CompletedPhase 3NCT00214604

Type III Dysbetalipoproteinemia

Studying Dysbetalipoproteinemia

Last synced from ClinicalTrials.gov May 8, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: AstraZeneca
Principal Investigator: AstraZeneca Crestor Medical Sciences Director, MD
AstraZeneca
Intervention: Rosuvastatin(drug)
Enrollment: 30 enrolled
Eligibility: 18 years · All sexes
Timeline: 2005 – 2007

Study locations (2)

Research Site, Oslo, Norway
Research Site, Cape Town, South Africa

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00214604 on ClinicalTrials.gov

Other trials for Dysbetalipoproteinemia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT07219602
A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
NewAmsterdam Pharma

See all trials for Dysbetalipoproteinemia →

← Back to all trials